- Home
- WFG vs MIRM Comparison
WFG vs MIRM Comparison
Compare WFG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | MIRM |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 7.2B |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WFG | MIRM |
|---|---|---|
| Price | $66.34 | $113.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $89.50 | ★ $119.85 |
| AVG Volume (30 Days) | 176.1K | ★ 734.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $5.05 | $26.22 |
| Revenue Next Year | $10.26 | $22.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.34 | $50.25 |
| 52 Week High | $76.99 | $130.00 |
Technical Indicators
Market Signals| Indicator | WFG | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 45.58 |
| Support Level | $63.55 | $87.93 |
| Resistance Level | $67.13 | $114.99 |
| Average True Range (ATR) | 2.05 | 5.09 |
| MACD | -0.40 | -1.87 |
| Stochastic Oscillator | 15.22 | 13.88 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.